Market closedADR
Adaptimmune Therapeutics/$ADAP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adaptimmune Therapeutics
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Ticker
$ADAP
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
506
Website
ADAP Metrics
BasicAdvanced
$62M
-
-$0.30
2.84
-
Price and volume
Market cap
$62M
Beta
2.84
52-week high
$1.48
52-week low
$0.20
Average daily volume
2.5M
Financial strength
Current ratio
2.916
Quick ratio
2.597
Long term debt to equity
586.547
Total debt to equity
626.289
Interest coverage (TTM)
-15.65%
Management effectiveness
Return on assets (TTM)
-12.39%
Return on equity (TTM)
-275.74%
Valuation
Price to revenue (TTM)
0.34
Price to book
5.18
Price to tangible book (TTM)
7.71
Price to free cash flow (TTM)
-0.798
Growth
Revenue change (TTM)
195.34%
Earnings per share change (TTM)
-47.03%
3-year revenue growth (CAGR)
207.07%
3-year earnings per share growth (CAGR)
-33.50%
What the Analysts think about ADAP
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adaptimmune Therapeutics stock.
ADAP Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADAP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADAP News
AllArticlesVideos
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Newsfile Corp·4 weeks ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adaptimmune Therapeutics stock?
Adaptimmune Therapeutics (ADAP) has a market cap of $62M as of April 17, 2025.
What is the P/E ratio for Adaptimmune Therapeutics stock?
The price to earnings (P/E) ratio for Adaptimmune Therapeutics (ADAP) stock is 0 as of April 17, 2025.
Does Adaptimmune Therapeutics stock pay dividends?
No, Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Adaptimmune Therapeutics dividend payment date?
Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders.
What is the beta indicator for Adaptimmune Therapeutics?
Adaptimmune Therapeutics (ADAP) has a beta rating of 2.84. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.